Literature DB >> 18415706

Validation of Chinese Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in patients scheduled for total knee replacement.

Feng Xie1, Shu-Chuen Li, Ron Goeree, Jean-Eric Tarride, Daria O'Reilly, Ngai-Nung Lo, Seng-Jin Yeo, Kuang-Ying Yang, Julian Thumboo.   

Abstract

OBJECTIVE: Our aim was to cross-culturally validate Chinese Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in patients with knee osteoarthritis (OA) scheduled for total knee replacement in Singapore.
METHODS: Chinese WOMAC was translated from the original English version following standard guidelines. Patients were asked to complete a questionnaire containing the WOMAC (twice within 6 days), the Short Form 36 (SF-36), and the EuroQoL EQ-5D. Reliability was assessed using Cronbach's alpha and intraclass correlation coefficients (ICC), dimensionality using item-to-domain correlations and factor analyses. Convergent and discriminant construct validity was assessed using six each a priori hypotheses.
RESULTS: Chinese WOMAC was well accepted by the patients in the pilot test. The Chinese and English versions were therefore administered to a consecutive sample of 131 Chinese- and 127 English-speaking subjects, respectively, with knee OA. Cronbach's alpha exceeded 0.7 for all domains except for Chinese pain domain, whereas the ICC exceeded 0.7 for all domains. Hypothesized item-to-domain correlations were observed for all items except for four items in Chinese physical function domain. The factor analyses yielded seven and five factors with eigenvalues of more than 1.0 in the Chinese and English versions, respectively. A total of 10/12 a priori construct validity hypotheses were satisfied for the Chinese version. Weak correlations between WOMAC pain and SF-36 bodily pain and moderate correlation between WOMAC pain and EQ-5D anxiety/depression were observed.
CONCLUSIONS: Chinese WOMAC was well accepted and demonstrated acceptable psychometric properties in Singaporean patients with severe knee OA.

Entities:  

Mesh:

Year:  2008        PMID: 18415706     DOI: 10.1007/s11136-008-9340-7

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  15 in total

1.  Validity and reliability of Swedish WOMAC osteoarthritis index: a self-administered disease-specific questionnaire (WOMAC) versus generic instruments (SF-36 and NHP).

Authors:  P Söderman; H Malchau
Journal:  Acta Orthop Scand       Date:  2000-02

Review 2.  EQ-5D: a measure of health status from the EuroQol Group.

Authors:  R Rabin; F de Charro
Journal:  Ann Med       Date:  2001-07       Impact factor: 4.709

3.  A community-based study of scaling assumptions and construct validity of the English (UK) and Chinese (HK) SF-36 in Singapore.

Authors:  J Thumboo; K Y Fong; D Machin; S P Chan; K H Leon; P H Feng; S T Thio; M L Boe
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

4.  Validation of a modified Thai version of the Western Ontario and McMaster (WOMAC) osteoarthritis index for knee osteoarthritis.

Authors:  Vilai Kuptniratsaikul; Manee Rattanachaiyanont
Journal:  Clin Rheumatol       Date:  2007-02-20       Impact factor: 2.980

5.  Defining arthritis and measuring functional status in elders: methodological issues in the study of disease and physical disability.

Authors:  A A Guccione; D T Felson; J J Anderson
Journal:  Am J Public Health       Date:  1990-08       Impact factor: 9.308

6.  The algofunctional indices for hip and knee osteoarthritis.

Authors:  M G Lequesne
Journal:  J Rheumatol       Date:  1997-04       Impact factor: 4.666

Review 7.  Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines.

Authors:  F Guillemin; C Bombardier; D Beaton
Journal:  J Clin Epidemiol       Date:  1993-12       Impact factor: 6.437

8.  Cross-cultural adaptation and validation of Korean Western Ontario and McMaster Universities (WOMAC) and Lequesne osteoarthritis indices for clinical research.

Authors:  S C Bae; H S Lee; H R Yun; T H Kim; D H Yoo; S Y Kim
Journal:  Osteoarthritis Cartilage       Date:  2001-11       Impact factor: 6.576

9.  Generic and condition-specific outcome measures for people with osteoarthritis of the knee.

Authors:  J E Brazier; R Harper; J Munro; S J Walters; M L Snaith
Journal:  Rheumatology (Oxford)       Date:  1999-09       Impact factor: 7.580

10.  A comparison of the EuroQol-5D and the Health Utilities Index mark 3 in patients with rheumatic disease.

Authors:  Nan Luo; Ling-Huo Chew; Kok-Yong Fong; Dow-Rhoon Koh; Swee-Cheng Ng; Kam-Hon Yoon; Sheila Vasoo; Shu-Chuen Li; Julian Thumboo
Journal:  J Rheumatol       Date:  2003-10       Impact factor: 4.666

View more
  39 in total

1.  The effects of tourniquet use in total knee arthroplasty: a randomized, controlled trial.

Authors:  Kai Wang; Songjia Ni; Zhichang Li; Qunjie Zhong; Rujun Li; Hu Li; Yan Ke; Jianhao Lin
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-01-08       Impact factor: 4.342

2.  Validation of the SF-12 among adult Kashin-Beck disease patients in Aba Tibetan autonomous area in China.

Authors:  Qiang Huang; Zong Ke Zhou; Bin Shen; Xiao Bo Yang; Yong Li; Peng De Kang; Jing Yang; Fu Xing Pei
Journal:  Rheumatol Int       Date:  2012-05-08       Impact factor: 2.631

3.  Influence of pain severity on health-related quality of life in Chinese knee osteoarthritis patients.

Authors:  Jian Pang; Yue-Long Cao; Yu-Xin Zheng; Ning-Yang Gao; Xue-Zong Wang; Bo Chen; Xin-Feng Gu; Weian Yuan; Ming Zhang; Ting Liu; Hong-Sheng Zhan; Yin-Yu Shi
Journal:  Int J Clin Exp Med       Date:  2015-03-15

4.  Reliability and validation of the joint dysfunction index as a new assessment instrument for therapeutic efficacy for Kashin-Beck disease.

Authors:  Fang-Fang Yu; Chuan-Tao Xia; Hua Fang; Di-Miao Wang; Xiong Guo
Journal:  Clin Rheumatol       Date:  2016-04-19       Impact factor: 2.980

5.  The visual analogue WOMAC 3.0 scale--internal validity and responsiveness of the VAS version.

Authors:  Paula Kersten; Peter J White; Alan Tennant
Journal:  BMC Musculoskelet Disord       Date:  2010-04-30       Impact factor: 2.362

6.  Chinese adaptation and validation of the Knee Injury and Osteoarthritis Outcome Score (KOOS) in patients with knee osteoarthritis.

Authors:  Roy T H Cheung; Shirley P C Ngai; Kevin K W Ho
Journal:  Rheumatol Int       Date:  2016-07-23       Impact factor: 2.631

Review 7.  Patient-Reported Measures of Physical Function in Knee Osteoarthritis.

Authors:  Daniel K White; Hiral Master
Journal:  Rheum Dis Clin North Am       Date:  2016-03-17       Impact factor: 2.670

8.  Clinimetric properties of WOMAC Index in Greek knee osteoarthritis patients: comparisons with both self-reported and physical performance measures.

Authors:  George Papathanasiou; Sophia Stasi; Leon Oikonomou; Ioanna Roussou; Effie Papageorgiou; Efstathios Chronopoulos; Nectarios Korres; Nicholas Bellamy
Journal:  Rheumatol Int       Date:  2014-05-29       Impact factor: 2.631

9.  Efficacy of Intra-Articular Hypertonic Dextrose (Prolotherapy) for Knee Osteoarthritis: A Randomized Controlled Trial.

Authors:  Regina Wing Shan Sit; Ricky Wing Keung Wu; David Rabago; Kenneth Dean Reeves; Dicken Cheong Chun Chan; Benjamin Hon Kei Yip; Vincent Chi Ho Chung; Samuel Yeung Shan Wong
Journal:  Ann Fam Med       Date:  2020-05       Impact factor: 5.166

Review 10.  Measures of knee function: International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form, Knee Injury and Osteoarthritis Outcome Score (KOOS), Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS), Knee Outcome Survey Activities of Daily Living Scale (KOS-ADL), Lysholm Knee Scoring Scale, Oxford Knee Score (OKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Activity Rating Scale (ARS), and Tegner Activity Score (TAS).

Authors:  Natalie J Collins; Devyani Misra; David T Felson; Kay M Crossley; Ewa M Roos
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.